Hearing loss, cleft palate, and congenital hip dysplasia in female carriers of an intragenic deletion of AMMECR1

Abstract

Previously, mutations in the AMMECR1 gene have been described in six males with developmental delay, sensorineural hearing loss (SNHL) and/or congenital abnormalities, including fetal nuchal edema, fetal pericardial effusion, talipes, congenital hip dysplasia, elliptocytosis and cleft palate. In this report, we present three female relatives of a male fetus with an intragenic deletion in this X‐linked gene. All three women reported hearing loss and one was born with a soft cleft palate and hip dysplasia. The audiograms showed mild to moderate SNHL with a variable pattern of the affected frequencies. Immunohistochemical analysis of fetal cochlea was performed confirming the expression of AMMECR1 in the human inner ear. Since hearing loss, cleft palate and congenital hip dysplasia were reported before in male AMMECR1 point mutation carriers and AMMECR1 is expressed in fetal inner ear, we suggest that female carriers may display a partial phenotype in this X‐linked condition.

1. INTRODUCTION

Deletions of the Xq22.3‐Xq23 region, including both AMMECR1 and COL4A5, are described as part of Alport syndrome with intellectual disability (mental retardation), midface hypoplasia, and elliptocytosis (AMME) (Vitelli et al., 2000). Until now, 10 male patients with a deletion including AMMECR1 have been described (Lu et al., 2021).

Although AMMECR1 and some of its functions in mice have been known since 1999 (Vitelli et al., 1999), the first mutations in the gene in humans have not been reported until recently (Andreoletti et al., 2017). In 2017, single missense mutations in AMMECR1 were described in two half‐brothers with early speech and language delay, infantile hypotonia, hearing loss, nephrocalcinosis and midface hypoplasia with submucosal cleft and bifid uvula (Andreoletti et al., 2017) and in two males with elliptocytosis, midface hypoplasia, short stature, and hearing loss (Basel‐Vanagaite et al., 2017).

In this short report, we present signs and symptoms of three carrier female relatives of a male fetus with an intragenic hemizygous deletion in AMMECR1 suggesting that a partial phenotype may be present in females.

2. CASES

A woman, pregnant with dichorionic twins, was referred to our department of prenatal diagnostics because of an increased nuchal translucency of fetus B (Index III‐2). At a gestational age of 16 weeks, bilateral talipes, pericardial effusion, cardiomegaly, and mild tricuspid insufficiency was noted. Using SNP array, an intragenic deletion of AMMERC1 on Xq23.1 was found. This hemizygous in‐frame deletion encompassed exon 4 of the AMMECR1 gene. He was part of a dizygotic twin pregnancy; the other fetus (Patient III‐1) did not show any abnormalities at the ultrasound scan or at genetic investigation.

Three out of four reported point mutations to date were point mutations (one missense, two nonsense) in exon 4 of the AMMECR1 gene. Since talipes, pericardial effusion and cardiac anomalies have been described in patients with a missense mutation in AMMECR1 (Andreoletti et al., 2017; Basel‐Vanagaite et al., 2017; Moysés‐Oliveira et al., 2018), it is very likely that the intragenic deletion of AMMECR1 explains the phenotype of the fetus. Moreover, fetal blood from a cord puncture showed some elliptocytes and erythrocyte deformability was abnormal compared to healthy controls. However, since no age‐matched controls were available to quantify the result, there is no definite diagnosis of hereditary elliptocytosis.

The index was selectively terminated at 19 weeks on request of the parents. This fetus retained in utero until the term delivery of the surviving cotwin and therefore, the overt maceration of the body tissue impeded postnatal clinical examination.

The index' mother (Figure 1; Patient II‐1) has asymmetric mild to moderate sensorineural hearing loss (SNHL), for which a hearing aid was recently fitted on the worst hearing left ear. She had an episode of vestibular complaints in the past. Her pure tone audiogram (PTA) (Figure S1) showed a flat SNHL of 27 dB on the right ear and a midfrequency SNHL of 47 dB on the left ear. The index' maternal grandmother (Figure 1; Patient I‐1) has worn hearing aids since the age of 40 years. Her PTA (Figure S3) showed a symmetric flat SNHL of 60 dB. The index' maternal aunt (Figure 1; Patient II‐2) has congenital hip dysplasia, hearing problems with recurrent middle ear infections as a child and has had corrective surgery for a cleft of the soft palate. Her PTA (Figure S2) showed an asymmetric SNHL, mainly of the low frequencies.

FIGURE 1.

Three generations pedigree of this family showing hearing loss in all female carriers

Patients I‐1 and II‐2 did not report vestibular complaints. Hearing loss or congenital abnormalities did not occur in any other family member. No short stature, microsomia or midface hypoplasia was observed in I‐1 and II‐1. Although some mild hypotelorism was observed in II‐2, we could not assess the presence of midface hypoplasia since she was not able to come to the clinic for full dysmorphological examination.

Patients I‐1, II‐1, and II‐2 were all hemizygous female carriers of the intragenic deletion of AMMECR1. In Patient I‐1, no alternative genetic explanation for the hearing loss was found on next generation sequencing analysis (hearing impairment gene panel DG 2.18 Radboudumc [206 genes; not including AMMECR1]).

In the asymptomatic daughter and sister of Patient I‐1 (II‐3 and I‐2) the AMMECR1 deletion was not detected. The brother and the nephew of Patient I‐1 (I‐4 and II‐6) were phenotypically normal.

3. METHODS AND RESULTS OF CLINICAL GENETIC TESTING AND IMMUNOHISTOCHEMICAL ANALYSIS FOR AMMECR1 EXPRESSION IN FETAL COCHLEA

3.1. Array

The Affymetrix CytoScanHD SNP array showed an intragenic hemizygous deletion of 23 kb (24 probes), containing exon 4 of the AMMECR1 gene (NM_015365.2) (coordinates of estimated minimally deleted region: chrX: 109,496,686–109,520,211 bp [build GRCh37]); see also Figure S5. Subsequent testing in family members showed three female carriers of the deletion, as depicted in Figure 1.

3.2. X‐inactivation

X‐inactivation was assessed by determining the methylation status of the CAG repeat in the androgen receptor gene on the X chromosome (Kubota et al., 1999). AMMECR1 usually does not escape X chromosome inactivation (Cotton et al., 2015).

X‐inactivation patterns in peripheral blood showed skewing of 90:10 in Patient II‐2; borderline skewing of 80:20 in Patient II‐1 and random skewing of 60:40 in Patient I‐1.

3.3. Human fetal inner ear immunohistochemistry

Use of human embryonic and fetal specimens was in accordance with Dutch legislation (Fetal Tissue Act, 2001) and the WMA Declaration of Helsinki guidelines. Ethical approval was obtained in our institute (protocol registration number B18.044). Human fetal inner ears were collected after elective termination of pregnancy by vacuum aspiration. Fetal age (in weeks, W), defined as the duration since fertilization, was determined by obstetric ultrasonography prior to termination. Tissue was obtained at the developmental stages W13 (n = 1) and W17 (n = 1). Inner ears were fixed in 4% paraformaldehyde, decalcified and embedded in paraffin as previously described (van Beelen et al., 2020). Sections (5 μm) were cut using a HM 355S rotary microtome (Thermo Fisher Diagnostics). Sections were deparaffinized in xylene and rehydrated, followed by standard immunohistochemistry procedures (Locher et al., 2013). Sections were incubated overnight at +4°C with a polyclonal rabbit anti‐AMMECR1 antibody (1:50; #201552‐T10; Sino Biological). Next, sections were incubated with a secondary AF488 donkey anti‐rabbit antibody (1:1000; #A‐21206; Invitrogen) for 1 h at room temperature. Nuclei were stained with DAPI. Negative controls were carried out by matching isotype controls and omitting primary antibodies. Positive controls were carried out by staining sections of known positive human tissue samples. At least three separate immunostaining experiments for each fetal stage were performed.

The immunohistochemistry shows expression of AMMECR1 in the human fetal inner ear (Figure S4). At Day 13, membranal expression of AMMECR1 is seen in most developing epithelial cells. At Day 17, expression of AMMECR1 is confined to the apical cells of Reissner's membrane, Kölliker's Organ, and the outer sulcus cells, suggesting a temporal gradient in expression.

4. DISCUSSION

In most cases of known AMMECR1 point mutation carriers with SNHL reported in the literature and summarized in Table 1, the SNHL was detected during childhood and the affected frequencies varied from flat to high frequency hearing loss. The severity of the hearing loss also varied and possible progression was observed in some cases. In the present study, an age‐related progression could be present but data are insufficient for conclusions.

TABLE 1.

Phenotypic features of the index patient and his female relatives and of known AMMECR1 point mutation carriers in literature

Tables	(Male) index	Mother	Maternal aunt	Grandmother	Basel‐Vanagaite et al. proband	Basel‐Vanagaite et al. maternal uncle	Andreoletti et al. proband II(1)	Andreoletti et al. proband II(2)	Andreoletti et al. proband I(2)	Moysés‐Oliveira P2	Moysés‐Oliveira P3
					c.1333C>T, p.(Arg45*)		c.530G>A, p.(Gly177Asp)			c.502C>T, p.(Arg168*)	c.429T>A, p.(Tyr143*)
Gender	M	F	F	F	M	M	M	M	F	M	M
Talipes	x						x
Fetal pericardial effusion	x				x
Tricuspid insufficiency	x
Fetal nuchal edema	x						x
Cleft palate			x		x		x	x
Hearing loss		x	x	x		x	x			x	x
Congenital hip dysplasia			x					x

Abbreviations: NM, not mentioned; x, present.

In this short report, we present a family in which female relatives of a male fetus with an AMMECR1 gene disruption have mild clinical features consistent with the male phenotype. Although partial phenotypes in female carriers of X‐linked disorders are not rare (Juchniewicz et al., 2018; Stembalska et al., 2016), a partial phenotype has not been reported for changes in the AMMECR1 gene before. Unilateral SNHL was also reported in the mother of two boys with a large deletion including not only AMMECR1, but also X‐linked Alport genes COL4A5 and the X‐linked deafness gene COL4A6 (Jonsson et al., 1998). Because of the combination with hematuria in this individual and her sons, it is hard to differentiate between the role of AMMECR1 and the deletion of COL4A5/COL4A6 as a cause of SNHL in this patient.

The first sign of the AMMECR1 deficiency in the male fetus was increased nuchal translucency. This was reported before by Andreoletti et al. (2017). Pericardial effusion (Basel‐Vanagaite et al., 2017) and talipes (Andreoletti et al., 2017) were also reported before.

Although the prevalence of hearing loss, cleft palate and congenital hip dysplasia is not extremely low in the general population, all of the features reported by the female carriers in this family were reported before in male point mutation carriers (Table 1). Therefore, we suggest that female carriers may show a partial phenotype. The expression of AMMECR1 in the human fetal inner ear (Figure S4) and the nonrandom X‐inactivation in the most severely affected female support this hypothesis.

Because of the possible reproductive consequences, we suggest to study AMMECR1 mutations and intragenic deletions in larger cohorts of patients with (mild) SNHL and/or cleft palate.

CONFLICT OF INTEREST

The authors have no conflicts of interest.

AUTHOR CONTRIBUTIONS

Saskia Koene: Writing manuscript. Jeroen Knijnenburg: DNA‐analysis and interpretation, correction of manuscript. Mariette J. V. Hoffer: DNA‐analysis and interpretation, correction of manuscript. Fleur Zwanenburg: Correction of manuscript. Monique C. Haak: Correction of manuscript. Heiko Locher: Generation of fetal cochlea data, correction of manuscript. Edward S. A. van Beelen: Generation of fetal cochlea data, correction of manuscript. Gijs W. E. Santen: First interpretation of genetic information; correction of manuscript. Liselotte J. C. Rotteveel: Interpretation of tone audiograms; corrections of manuscript.

Supporting information

Figure S1 Pure tone audiogram of mother of the index at age 33 years (patient II‐1)

Figure S2 Pure tone audiogram of maternal aunt of the index at age 38 years (patient II‐2)

Figure S3 Pure tone audiogram of maternal grandmother at age 62 years (patient I‐1)

Figure S4 AMMECR1 expression in the human fetal cochlea

Overview of the lower basal turn of the cochlea at W13 (A) and W17 (B) of development, immunostained with AMMECR1 (green). A) Membranal expression of AMMECR1 is seen in most developing epithelial cells, such as the stria vascularis (SV), Reissner's membrane (RM), the interdental cells (IC), Kölliker's Organ (KO), and the outer sulcus cells (OS). However, no expression was seen in the inner or outer hair cells (arrows) or in the spiral ligament (SL). B) At W17, expression of AMMECR1 is confined to the apical cells of Reissner's membrane (RM), Kölliker's Organ (KO), and the outer sulcus cells (OS), suggesting a temporal gradient in expression. Green: AMMECR1; blue: DAPI. Scale bar: 50 μm.

Figure S5 Visual representation of the AMMECR1 intragenic deletion detected with the CytoScanHD SNP array platform in the index patient and his mother (II‐1).

The upper probes panel shows the hemizygous deletion in the male index patient, plotted against a female reference. The lower probes panel shows the heterozygous deletion in the mother (II‐1), also plotted against a female reference.

Koene, S. , Knijnenburg, J. , Hoffer, M. J. V. , Zwanenburg, F. , Haak, M. C. , Locher, H. , van Beelen, E. S. A. , Santen, G. W. E. , & Rotteveel, L. J. C. (2022). Hearing loss, cleft palate, and congenital hip dysplasia in female carriers of an intragenic deletion of AMMECR1 . American Journal of Medical Genetics Part A, 188A:1578–1582. 10.1002/ajmg.a.62669

DATA AVAILABILITY STATEMENT

There is no data to share.